Nippon Kayaku's NK105 fails breast cancer Phase III

NK105 micellar paclitaxel from Nippon Kayaku Co. Ltd. (Tokyo:4272) missed the primary

Read the full 128 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE